Although LATS1/2 and FOXP3 expressions did not predict advanced GC, high LATS1/2 (HR = 1.304, 95% CI: 1.035–1.643, P = 0.024) and FOXP3 (HR = 1.320, 95% CI: 1.047–1.665, P = 0.019) expressions predicted shorter overall survival in patients with MSS GC. This evidence concerns the gene LATS1 and gastric cancer.